Fox News medical contributor Dr. Marc Siegel joins'Fox & Friends' to discuss the benefits of artificial intelligence in the medical industry if used with caution. Artificial intelligence is taking on an ever-widening role in the health and wellness space, assisting with everything from cancer detection to medical documentation. Soon, AI could make it easier for dentists to give patients a more natural, functional smile. Researchers from the University of Hong Kong recently developed an AI algorithm that uses 3D machine learning to design personalized dental crowns with a higher degree of accuracy than traditional methods, according to a press release from the university. The AI analyzes data from the teeth adjacent to the crown to ensure a more natural, precise fit than the crowns created using today's methods, the researchers said.
Ever year, more than a million people in North America suffer some form of spinal cord injury (SCI), with an annual cost of more than $7 billion to treat and rehabilitate those patients. The medical community has made incredible gains toward mitigating, if not reversing, the effects of paralysis in the last quarter-century including advances in pharmacology, stem cell technologies, neuromodulation, and external prosthetics. Electrical stimulation of the spinal cord has already shown especially promising results in helping spinal injury patients rehabilitate, improving not just extremity function but spasticity, bladder and blood pressure control as well. Now, in a study published in Nature Tuesday, SCI therapy startup Onward Medical, announced that it has helped improve a formerly-paraplegic man's walking gait through the use of an implanted brain computer interface (BCI) and novel "digital bridge" that spans the gap where the spine was severed. We've been zapping paraplegic patients' spines with low-voltage jolts as part of their physical rehabilitation for years in a process known as Functional Electrical Stimulation (FES).
Rishi Sunak is scrambling to update the government's approach to regulating artificial intelligence, amid warnings that the industry poses an existential risk to humanity unless countries radically change how they allow the technology to be developed. The prime minister and his officials are looking at ways to tighten the UK's regulation of cutting-edge technology, as industry figures warn the government's AI white paper, published just two months ago, is already out of date. Government sources have told the Guardian the prime minister is increasingly concerned about the risks posed by AI, only weeks after his chancellor, Jeremy Hunt, said he wanted the UK to "win the race" to develop the technology. Sunak is pushing allies to formulate an international agreement on how to develop AI capabilities, which could even lead to the creation of a new global regulator. Meanwhile Conservative and Labour MPs are calling on the prime minister to pass a separate bill that could create the UK's first AI-focused watchdog.
Google has finally removed a controversial mobile game that allowed players to buy, sell and even inflict torture on black characters. Called'Simulador de Escravidão' (or'Slavery Simulator'), the Android game for'all ages' was created by Malaysian games developer Magnus Games. It was released to Google's Play Store on April 20 and downloaded more than 1,000 times before it was removed on Wednesday following uproar on social media. But it still remains available to people who have already downloaded it, according to Brazilian daily newspaper Folha de S Paulo. It follows claims that the hugely popular FIFA football video game perpetuates racist myths and stereotypes about black people.
Neuralink has announced that the U.S. Food and Drug Administration (FDA) has approved the launch of its first clinical study in humans. "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study!" Neuralink's official Twitter account wrote on Thursday.(opens in a new tab) "This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people." The neurotechnology company isn't recruiting test subjects just yet, and hasn't released any information on exactly what the clinical trial will involve. Even so, fans of Neuralink founder Elon Musk are already chomping(opens in a new tab) at(opens in a new tab) the(opens in a new tab) bit(opens in a new tab) to implant questionable experimental technology in their grey matter. Neuralink aims to develop implantable devices that will let people control computers with their brain, as well as restore vision or mobility to people with disabilities.
Neuralink Corp., Elon Musk's brain-implant company, said it received approval from the US Food and Drug Administration to conduct human clinical trials. "This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," the company said Thursday in a tweet. The FDA and Neuralink did not immediately respond to requests for comment. Musk's startup is developing a small device that will link the brain to a computer, consisting of electrode-laced wires. Placing the device requires drilling into the skull. The approval "is really a big deal," said Cristin Welle, a former FDA official and an associate professor of neurosurgery and physiology at the University of Colorado.
United States regulators have given approval for Elon Musk's start-up Neuralink to test its brain implants on people. Neuralink said on Thursday that it received clearance from the US Food and Drug Administration (FDA) for the first human clinical study of implants which are intended to let the brain interface directly with computers. "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study," Neuralink said in a post on Twitter – which is owned by Musk. Neuralink prototypes, which are the size of a coin, have so far been implanted in the skulls of monkeys, demonstrations by the startup showed. With the help of a surgical robot, a piece of the skull is replaced with a Neuralink disk, and its wispy wires are strategically inserted into the brain, an early demonstration showed.
Neuralink, Elon Musk's brain-implant company, said on Thursday it had received a green light from the US Food and Drug Administration (FDA) to kickstart its first in-human clinical study, a critical milestone after earlier struggles to gain approval. Musk has predicted on at least four occasions since 2019 that his medical device company would begin human trials for a brain implant to treat severe conditions such as paralysis and blindness. Yet the company, founded in 2016, only sought FDA approval in early 2022 – and the agency rejected the application, seven current and former employees told Reuters in March. The FDA had pointed out several concerns to Neuralink that needed to be addressed before sanctioning human trials, according to the employees. Major issues involved the lithium battery of the device, the possibility of the implant's wires migrating within the brain and the challenge of safely extracting the device without damaging brain tissue.
Turns out Elon Musk's FDA prediction was only off by about a month. After reportedly denying the company's overtures in March, the FDA approved Neuralink's application to begin human trials of its prototype Link brain-computer interface (BCI) on Thursday. Founded in 2016, Neuralink aims to commercialize BCIs in wide-ranging medical and therapeutic applications -- from stroke and spinal cord injury (SCI) rehabilitation, to neural prosthetic controls, to the capacity "to rewind memories or download them into robots," Neuralink CEO Elon Musk promised in 2020. BCIs essentially translate the analog electrical impulses of your brain (monitoring it using hair-thin electrodes delicately threaded into that grey matter) into the digital 1's and 0's that computers understand. Since that BCI needs to be surgically installed in a patient's noggin, the FDA -- which regulates such technologies -- requires that companies conduct rigorous safety testing before giving its approval for commercial use.
Scientists using artificial intelligence have discovered a new antibiotic that can kill a deadly superbug. According to a new study published on Thursday in the science journal Nature Chemical Biology, a group of scientists from McMaster University and the Massachusetts Institute of Technology have discovered a new antibiotic that can be used to kill a deadly hospital superbug. The superbug in question is Acinetobacter baumannii, which the World Health Organization has classified as a "critical" threat among its "priority pathogens" – a group of bacteria families that pose the "greatest threat" to human health. According to the WHO, the bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well. A baumannii poses a threat to hospitals, nursing homes and patients who require ventilators and blood catheters, as well as those who have open wounds from surgeries.